VistaGen Therapeutics Inc (VTGN)

[MissionIR]

VistaGen Therapeutics Due Diligence Summary

Company Website
http://www.vistagen.com

VistaGen IR Kit
http://vsta.missionir.com/vsta

VistaGen Fact Sheet
http://vistagen.com/fact_sheet/index.html

Stock Info
http://finance.yahoo.com/q?s=VSTA.OB
http://www.otcmarkets.com/stock/VSTA/quote

Abbreviated Company Profile

VistaGen Therapeutics, Inc. is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of promising drug candidates that have been discontinued during preclinical development ("put on the shelf") due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential toxicity of promising new drug candidates long before they are ever tested on humans. VistaGen's human pluripotent stem cell-based bioassay systems more closely approximate human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development.

Key Investment Highlights

• Proprietary Stem Cell Technology Addressing Major Safety Challenges in Drug Development
• Drug Rescue Platform Designed to Recapture Prior R&D Investment in New Drug Candidates
• New Drug Candidate for Neuropathic Pain in NIH-funded Phase Ib Clinical Trials
• Management Team with Decades of Relevant Experience
• Stem Cell Technology Aimed at Saving Millions of Healthcare Dollars

Technology
http://www.vistagen.com/technology/default.aspx

Product Line
http://www.vistagen.com/products/Clinical-Trials-in-a-Test-Tube/default.aspx

Business Model
http://www.vistagen.com/business-model/default.aspx

VistaGen Youtube Page
http://www.youtube.com/user/VistaGenVSTA

Share Structure

Shares Outstanding 15,241,904 a/o November 17, 2011
Authorized Shares 200,000,000 a/o October 28, 2011 (recently reduced http://owl.li/7emyV)

Management

Shawn Singh, JD, Chief Executive Officer, Director

Mr. Singh has over 20 years of experience working with public and private biotechnology and pharmaceutical companies, serving in numerous senior management roles. Prior to joining us as Chief Executive Officer in August 2009, he served as Managing Principal of Cato BioVentures, a biopharmaceutical venture capital firm currently VistaGen’s second largest institutional investor, Chief Business Officer of Cato Research Ltd., a global contract research and development organization (CRO), President of Echo Therapeutics (Nasdaq:ECTE), a medical device company targeting diabetes management, and Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), a revenue-producing specialty pharmaceutical company focused on cancer and infectious disease. Mr. Singh currently serves as a director of Echo Therapeutics and Armour Therapeutics. He began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP, an international law firm. Mr. Singh is a member of the State Bar of California.

Ralph Snodgrass, PhD, President, Chief Scientific Officer, Director

Dr. Snodgrass founded VistaGen in 1998 and served as our Chief Executive Officer until August 2009. He has over 18 years of experience in senior biotechnology management, including as Chief Scientific Officer of Progenitor, Inc. He has more than 10 years of research experience as a professor at the Lineberger Comprehensive Cancer Center, University North Carolina Chapel Hill School of Medicine, and as a member of the Institute for Immunology, Basel, Switzerland. Dr. Snodgrass is a past Board Member of the Emerging Company Section of the Biotechnology Industry Organization (BIO), and is a published and recognized pioneering expert in stem cell biology with more than 20 years’ experience in the uses of stem cells as biological tools for drug discovery and development.

Gordon Keller, PhD, Chairman, Scientific Advisory Board

Dr. Keller, recently named a “Top 25 Transformational Canadian” for his stem cell research, is the Director of UHN’s McEwen Centre, and Professor, Department of Medical Biophysics, University of Toronto, Ontario. Dr. Keller is a world leader in the field of hematopoietic development with more than 100 publications relating to blood development and stem cells. Previously, he held an endowed Chair at the Carl C. Icahn Institute for Gene Therapy and Molecular Medicine, MSSM, was a Member of the NJH, Denver, Colorado, Associate Professor, Department of Immunology, University Health Sciences Center, Denver, Colorado, a Member, Basel Institute for Immunology, Basel, Switzerland, and a Visiting Scientist at the Research Institute of Molecular Pathology, Vienna, Austria. He has served on several NIH study sections and is invited throughout the world to talk about his research on stem cells and blood development. Dr. Keller and Dr. Snodgrass are long-time collaborators who helped pioneer the use of stem cell systems for understanding hematopoietic development and cell biology, and as better biological systems for pharmaceutical discovery, rescue and development.

Jon S. Saxe, Chairman, Board of Directors

Mr. Saxe has served as Chairman of our Board of Directors since 2000. He is the retired President and previously a director of PDL BioPharma. He also served as President, Chief Executive Officer and a director of Synergen, Inc. (acquired by Amgen) as well as Vice President, Licensing & Corporate Development and Head Patent Law for Hoffmann-Roche. Mr. Saxe is currently a director of SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), Durect Corporation (Nasdaq: DRRX), Arbor Vita Corporation and Arcuo Medical, LLC. He also has served as a director of several other biotechnology and pharmaceutical companies, including ID Biomedical (acquired by GlaxoSmithKline), Sciele Pharmaceuticals, Inc. (acquired by Shionogi), Amalyte (acquired by Kemin Industries), and Cell Pathways (acquired by OSI Pharmaceuticals)

Franklin Rice, MBA, Chief Financial Officer

Mr. Rice joined VistaGen in 1999. He has been employed in the biotechnology industry since 1988 during which time he has served as Senior Director of Business Development at Genencor International and Vice President of Biotechnology and Pharmaceuticals for Bechtel Group where he was responsible for global sales and marketing of consulting services to biotechnology and pharmaceutical companies.

Transfer Agent

Holladay Stock Transfer
2939 N. 67th Place
Scottsdale, AZ, 85251
480-481-3940

Company Contact

VistaGen Therapeutics, Inc.
South San Francisco, California
http://www.vistagen.com
T: 650-244-9990
E: [e-mail]

IR Contact

Mission Investor Relations
Atlanta, Georgia
http://www.missionir.com
T: [phone]
E: [e-mail]